o     Nykode showcases proprietary machine learning platform for multi-antigen
immunotherapy optimization at leading industry conference in Zurich

Oslo, Norway, April 30, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a clinical
stage biopharmaceutical company dedicated to the discovery and development of
novel immunotherapies, today presents its proprietary artificial intelligence
(AI) capabilities at the 25th BioPharma Drug Discovery Nexus conference, taking
place in Zurich, Switzerland on 29-30 April 2026.

Nykode Therapeutics will deliver a presentation titled "From Precision to
Performance: AI-Powered Strategies for Optimal Immunotherapies Design",
highlighting how the Company is leveraging AI and machine learning (ML) to
accelerate and enhance its immunotherapy discovery pipeline. Key highlights from
the presentation include:

o	Predictive design modelling: Nykode has developed AI capabilities that enable
the Company to model the impact of immunotherapy design choices on protein
integrity, folding, and cellular secretion prior to laboratory experimentation,
materially reducing time and resource requirements in early-stage discovery

o	Large-scale construct evaluation: Nykode's proprietary ML models support the
simultaneous evaluation of thousands of multi-antigen immunotherapy constructs,
systematically prioritising candidate designs against defined criteria for
immunogenicity and biophysical properties.

o	Interpretable AI: Nykode develops proprietary models and runs them alongside
interpretable models, enabling scientists to understand the molecular features
driving optimal design selection and apply informed scientific judgment at each
stage of the pipeline.

o	Human-on-the-loop philosophy: Nykode operates a human-on-the-loop framework in
which AI serves to augment rather than replace scientific expertise, with
qualified oversight embedded throughout the discovery and development process

"At Nykode, applying AI to immunotherapy design is not new as it has been
central to how we have built and refined our platform for years. Today's
presentation reflects how deeply embedded these capabilities have become in the
way we work. Our machine learning models allow us to make smarter, faster
decisions about which immunotherapy candidates to advance and, crucially, our
scientists understand and trust the outputs because interpretability is built
into our approach from the start. We believe this combination of longstanding AI
capability and human oversight is what distinguishes a truly effective AI-driven
discovery process," said Michael Engsig, Chief Executive Officer at Nykode
Therapeutics.

The presentation will be available after the session at the Company's Webpage:
https://nykode.com/research-and-development/scientific-papers-and-presentations/


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in first line
head and neck cancer with the randomized Abili-T trial with interim results
within 2027. 

VB10.NEO, an individualized cancer neoantigen immunotherapy, has been
investigated in two trials with more than 10 different indications.
 
Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway